Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

While GLP‑1 receptor agonists may be best known for aiding weight loss and regulating digestion, gastroenterologists are also drawing attention to the therapies’ effect on the brain. Indeed, recent ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...